MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Item

http://www.wikidata.org/entity/Q35605418

Q35605418

about

Biologicals in rheumatoid arthritis: current and future Pivotal roles of GM-CSF in autoimmunity and inflammation Secreted trophic factors of mesenchymal stem cells support neurovascular and musculoskeletal therapies Emerging Therapies for Rheumatoid Arthritis GM-CSF: An immune modulatory cytokine that can suppress autoimmunity Multiple Sclerosis and T Lymphocytes: An Entangled Story Pathogenic Inflammation and Its Therapeutic Targeting in Systemic Lupus Erythematosus Potential role of granulocyte-monocyte colony-stimulating factor in the progression of intracranial aneurysms.Randomized phase 1b trial of MOR103, a human antibody to GM-CSF, in multiple sclerosis.Neutralization and clearance of GM-CSF by autoantibodies in pulmonary alveolar proteinosis.Dual Role of GM-CSF as a Pro-Inflammatory and a Regulatory Cytokine: Implications for Immune Therapy.CSF2 Overexpression Is Associated with STAT5 Phosphorylation and Poor Prognosis in Patients with Urothelial Carcinoma.Preclinical characterisation of the GM-CSF receptor as a therapeutic target in rheumatoid arthritis.Evolution of phage display technology: from discovery to application.Recent Advances in Monoclonal Antibody Therapies for Multiple Sclerosis.Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives.Phase 1b randomized, double-blind study of namilumab, an anti-granulocyte macrophage colony-stimulating factor monoclonal antibody, in mild-to-moderate rheumatoid arthritis.Targeting GM-CSF in inflammatory diseases.Old and new therapeutics for Rheumatoid Arthritis: in vivo models and drug development.Evaluation of the Effect of a Single Intra-articular Injection of Allogeneic Neonatal Mesenchymal Stromal Cells Compared to Oral Non-Steroidal Anti-inflammatory Treatment on the Postoperative Musculoskeletal Status and Gait of Dogs over a 6-Month Pe Selected cytokine pathways in rheumatoid arthritis.Dendritic cells as therapeutic targets in neuroinflammation.Biological role of granulocyte macrophage colony-stimulating factor (GM-CSF) and macrophage colony-stimulating factor (M-CSF) on cells of the myeloid lineage.Spotlight on mavrilimumab for the treatment of rheumatoid arthritis: evidence to date The barrier hypothesis and Oncostatin M: Restoration of epithelial barrier function as a novel therapeutic strategy for the treatment of type 2 inflammatory disease.GM-CSF signalling blockade and chemotherapeutic agents act in concert to inhibit the function of myeloid-derived suppressor cells in vitro.Therapeutic Targeting of the G-CSF Receptor Reduces Neutrophil Trafficking and Joint Inflammation in Antibody-Mediated Inflammatory Arthritis.A Frameshift in CSF2RB Predominant Among Ashkenazi Jews Increases Risk for Crohn's Disease and Reduces Monocyte Signaling via GM-CSF.Human Adipose-Derived Mesenchymal Stem Cells Modulate Experimental Autoimmune Arthritis by Modifying Early Adaptive T Cell Responses.GM-CSF in murine psoriasiform dermatitis: Redundant and pathogenic roles uncovered by antibody-induced neutralization and genetic deficiency.Phage display-derived human antibodies in clinical development and therapy Depletion of CD4+ CD25+ regulatory T cells confers susceptibility to experimental autoimmune encephalomyelitis (EAE) in GM-CSF-deficient Csf2-/- mice.Molecular basis of in vitro affinity maturation and functional evolution of a neutralizing anti-human GM-CSF antibody.Design considerations and analysis planning of a phase 2a proof of concept study in rheumatoid arthritis in the presence of possible non-monotonicity Targeting granulocyte-macrophage colony-stimulating factor in epithelial and vascular remodeling in experimental eosinophilic esophagitis.Adipose-derived mesenchymal stromal cells modulate experimental autoimmune arthritis by inducing an early regulatory innate cell signature.Unique transcriptome signatures and GM-CSF expression in lymphocytes from patients with spondyloarthritis.GM-CSF as a therapeutic target in autoimmune diseases.Driving chronicity in rheumatoid arthritis - perpetuating role of myeloid cells.Investigational therapies targeting the granulocyte macrophage colony-stimulating factor receptor-α in rheumatoid arthritis: focus on mavrilimumab.

P2860

Q26780316-30A64392-3B3B-46D3-8DAC-B92D8461DF24 Q26830824-A7BF11E2-ED44-434C-A5A6-E35E77AEA291 Q28069890-9A33EC14-E355-4142-A0B5-60815CD64E35 Q28078943-2757AB0B-B274-4E3E-B76A-30B9673FE271 Q28080640-30D3F6BB-699E-4519-BB41-9366DBA41133 Q28086853-76D27B88-C692-4359-B3EB-12A945D315AD Q28088753-A66A479C-6D9F-4D9E-AC69-8A77D4A99F9F Q30361774-2B0AF5D1-193C-4339-8DDC-F024D5915E57 Q35639941-4C7CE424-A105-479F-B82E-4F9DFE651F36 Q35768564-94B02C88-BCA1-4F87-85DD-1176A27058F7 Q35928330-B94B0E9A-63DE-4318-A773-330C24D3184B Q35989342-32B6AC9F-A135-4503-8A0D-21B66F69C520 Q36150157-A785D2BB-510F-48E8-B689-00B7E50507AB Q36183954-D1AB7140-8D70-4301-804A-361EFFB578D8 Q37019872-E5CCF06E-BBA2-4AD4-A608-C57FFBF6A9CA Q37494846-274106FD-DBAC-44C7-BB29-47E7969A98AB Q37690033-6337EFBA-AF8D-4E28-A360-45831A038154 Q38657999-7B7FD0A1-CE65-42DD-999A-E5ED20169B4E Q38697262-8E2ED000-41F8-4FC3-A642-9501F2EFF50C Q38712913-59129841-D3EE-493B-B575-8D5BD7E2BEC8 Q38755912-3E7FE680-01EE-4EB6-908F-A0679E20E55F Q38771884-8A6D64B3-9189-485C-B109-1A1A31B18EBE Q38880272-0B7D553B-C877-42C9-9CAC-17DF4C120060 Q38988087-00D9723B-EEF0-4683-874A-62206FBEC6DE Q39407129-87906BA0-B232-430E-A270-F6C8FFC89D56 Q40032613-44CCF16E-E72F-435B-8975-D48E4C5E9DBA Q40468456-DE956389-E843-4FF3-AF6F-9271120007EB Q40667799-B242128F-DDF6-4E58-A8F0-D30859063137 Q40702107-4A2FB2BC-4F8C-461F-81F8-B1E48BD4A703 Q41255523-2115CB9C-4B58-4AD3-AC3E-140ABE09FFC6 Q41416393-FEB2D1C4-104A-49A2-BB7C-2F0D05473CA5 Q41649247-259FBD10-F886-486A-8CF2-825542FF95D6 Q41763168-F54DD8B9-5703-4C14-99AF-FA619A1D002A Q42142601-9E6CFBE5-578F-4124-9DE2-0C26BBDB8353 Q42502746-983E8362-A6B7-4D5D-871C-4BC5F0B404BC Q42763577-13D7FAF6-470F-4001-B6CB-0FD069B59943 Q47100895-BCD9E305-F673-458D-A7EC-6C649C5E81BF Q47138480-7C0DEEF6-4CC6-4C7C-9ACA-FA8FA2651BC1 Q47189951-A357AC51-04B2-4E83-A962-6F58C13E2A56 Q49393096-3A0B0863-F3A0-4417-99AC-4D5FF28DF445

P2860

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

Item

http://www.wikidata.org/entity/Q35605418

description

2014 nî lūn-bûn

@nan

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

2014年论文

@zh

2014年论文

@zh-cn

name

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@ast

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@en

type

Item

label

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@ast

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@en

prefLabel

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@ast

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@en

P1476

MOR103, a human monoclonal ant ...... rolled, dose-escalation trial.

@en

P2093

Andrea Rubbert-Roth

http://www.w3.org/2001/XMLSchema#string

Arndt J Schottelius

http://www.w3.org/2001/XMLSchema#string

Bo J Ejbjerg

http://www.w3.org/2001/XMLSchema#string

Frank Behrens

http://www.w3.org/2001/XMLSchema#string

Harald Burkhardt

http://www.w3.org/2001/XMLSchema#string

Jens Geiseler

http://www.w3.org/2001/XMLSchema#string

Juergen Rech

http://www.w3.org/2001/XMLSchema#string

Julia Fresenius

http://www.w3.org/2001/XMLSchema#string

Mariusz Korkosz

http://www.w3.org/2001/XMLSchema#string

Mikkel Østergaard

http://www.w3.org/2001/XMLSchema#string

P2860

Blockade of collagen-induced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease

The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis

In vitro affinity maturation of human GM-CSF antibodies by targeted CDR-diversification.

Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-α, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study

Modified disease activity scores that include twenty-eight-joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis.

Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis

Development and validation of the European League Against Rheumatism response criteria for rheumatoid arthritis. Comparison with the preliminary American College of Rheumatology and the World Health Organization/International League Against Rheumati

The encephalitogenicity of T(H)17 cells is dependent on IL-1- and IL-23-induced production of the cytokine GM-CSF.

OMERACT Rheumatoid Arthritis Magnetic Resonance Imaging Studies. Core set of MRI acquisitions, joint pathology definitions, and the OMERACT RA-MRI scoring system.

Efficacy and safety of the fully human anti-tumour necrosis factor alpha monoclonal antibody adalimumab (D2E7) in DMARD refractory patients with rheumatoid arthritis: a 12 week, phase II study.

P304

1058-1064

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1136/ANNRHEUMDIS-2013-204816

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

P577

2014-02-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

260241449

http://www.w3.org/2001/XMLSchema#string

P698

24534756

http://www.w3.org/2001/XMLSchema#string

P921

macrophage

placebo

antibody

P932

4431325

http://www.w3.org/2001/XMLSchema#string

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

about

P2860

P2860

MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebo-controlled, dose-escalation trial.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P407

P433

P478

P50

P577

P5875

P698

P921

P932